AQ
AQST.O
—
NASDAQ
Pharmaceuticals
Aquestive Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
462,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-159,5 %
ROE
248,9 %
Net margin
-188,1 %
Debt / equity
-1,34
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,77
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Aquestive Therapeutics Inc operates in the pharmaceuticals sector, developing and commercializing drug products within the health care industry.
Business. Aquestive Therapeutics Inc (AQST.O) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY9 analysts
9 buy0 hold0 sell
Avg 12m price target8,89
Analyst recommendations
9 analysts · consensus BuyBuy9
Hold0
Sell0
12-month price target
8,89
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
9 analysts · indicative
Ownership→
Wells Fargo Advisors
largest disclosed fund holder
Profitability→
248,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AQST.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Aquestive Therapeutics Inc (AQST.O) is a pharmaceutical company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDAquestive Therapeutics maintains a negative equity position of -$33.7 million against total liabilities of $194.1 million, resulting in a debt-to-equity ratio of -1.34. The balance sheet reflects $45.0 million in long-term debt and total assets of $160.4 million. Operating cash flow is negative at -$52.4 million, while capital expenditures remain minimal at $0.6 million. The company carries a market capitalization of $452.4 million, implying a significant premium over its book value despite the negative equity. Liquidity risk is assessed as medium, with key flags noting that net cash is negative after subtracting total debt.
Profitability metrics indicate substantial losses, with net income at -$83.8 million and operating income at -$71.1 million for the latest period. Return on assets is -0.52, reflecting the inability to generate earnings from its asset base. Return on equity is reported as 2.49, a metric that is distorted by the negative equity denominator and should be interpreted with caution. The EV/EBITDA ratio is negative at -7.0, consistent with the company's pre-profitability status. Revenue stands at $44.5 million, yielding an EV/Revenue multiple of 11.17, which suggests the market is pricing in significant future growth or asset value not currently reflected in earnings.
Key takeaways
- Aquestive Therapeutics reports negative equity of -$33.7 million and negative net cash, posing medium liquidity risk.
- The company generated $44.5 million in revenue but incurred an $83.8 million net loss, resulting in negative ROA and distorted ROE.
- Analyst sentiment is strongly positive, with a mean price target of $8.89, implying a 140% upside from the current $3.71 price.
- Dilution risk is assessed as low, with basic and diluted shares outstanding identical at 122.0 million.
- Valuation multiples are high (EV/Revenue 11.17) and negative (EV/EBITDA -7.0), reflecting pre-profitability status and growth expectations.
- Lack of historical data and segment breakdowns limits the depth of trend and concentration analysis.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$3,79
Market cap
$452.4M
Enterprise valueⓘ
$497.4M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$33.7M
Net cashⓘ
-$45.0M
Current ratioⓘ
—
Debt / equityⓘ
-1.3
ROAⓘ
-52.2%
ROEⓘ
2.5%
Cash conversionⓘ
63.0%
CapEx / revenueⓘ
1.3%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships3 disclosed relationships · 2 types · extracted from filings & disclosures
Customers1
Indivior Pharmaceuticals IncINDV.OCustomer88%Source ↗
Partners2
Indivior Pharmaceuticals IncINDV.OPartner95%Source ↗
Zevra Therapeutics IncZVRA.OPartner95%Source ↗
Supply chain
Vendors → AQST ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 33 %
EPS
Consensus EPS
-0,48
Predicted surprise
-0,02
Beat probability
33 %
Analysts
9
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-26 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,41 |
| Revenue | —no estimate | —no estimate | 50,6M USD |
| Operating income | —no estimate | —no estimate | -42,5M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution9 analysts
Strong buy2
Buy7
Hold0
Sell0
Strong sell0
12-month price target$8,89 · Median $9,00
Low $6,00High $11,00
Operating income · consensus-42,5M USD
EPS surprise
−63,0 %
reported vs consensus · miss
Revenue surprise
−11,9 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$6,00
Mean$8,89
Median$9,00
High$11,00
Spot$3,79
+134.5 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-159,5 %Bottom quartile
Net Margin-188,1 %Bottom quartile
ROE248,9 %Best in class
Capex / Rev1,3 %Above P75
D/E-1,34Best in class
Cash Conv0,63Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 252 000 sh1 exercises · 7 grants7 insiders
- Director · Non-Qualified Stock Option (right to buy) → Common StockDisposed 25 000 @ $0,71exercise · 2026-06-23
- Director · Non-Qualified Stock Option (right to buy) → Common StockDisposed 50 500 @ $3,99grant · 2026-06-10
- Director · Stock Option (Right to Purchase) → Common StockAcquired 50 500 @ $3,99grant · 2026-06-10
- Director · Stock Option (Right to Purchase) → Common StockAcquired 50 500 @ $3,99grant · 2026-06-10
- Director · Stock Option (right to purchase) → Common StockAcquired 50 500 @ $3,99grant · 2026-06-10
- Director · Stock Option (Right to Purchase) → Common StockAcquired 50 500 @ $3,99grant · 2026-06-10
- Director · Stock Option (Right to Purchase) → Common StockAcquired 50 500 @ $3,99grant · 2026-06-10
- Chief Legal Officer · Non-Qualified Stock Option (right to buy) → Common StockAcquired 75 000 @ $4,13grant · 2026-05-18
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Capex To Revenuecapital_expenditure / revenue
Source documents
- Aquestive Therapeutics, Inc. Market data — financials · 2026-07-26
- reconciler_enqueue (reconciler) on AQST.O · 2026-07-26
- Aquestive Therapeutics Inc Market data — analyst estimates · 2026-07-26
- Aquestive Therapeutics Inc HA canonical relationships · 2026-07-26
Ownership & reference
Top holders
- Brokerage Firms · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2025-12-310,00 %$38M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-06-300,00 %$14M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Daniel BarberPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 5 sellsnet -$365K9 insiders · last 365d
- President and CEO · Common StockSold 20 369 @ $4,00$82K · 2026-07-16
- President and CEO · Common StockSold 4 631 @ $4,03$19K · 2026-07-15
- Director · Common StockSold 25 000 @ $5,02$125K · 2026-06-23
- Director · Common StockOther 25 000 @ $0,71$18K · 2026-06-23
- President and CEO · Common StockSold 25 000 @ $4,16$104K · 2026-06-15
- Chief Commercial Officer · Common StockOther 2 714 · 2026-06-08
- Chief Legal Officer · Common StockOther 100 000 · 2026-05-18
- SVP, Regulatory Affairs · Common StockOther 1 667 @ $4,17$7K · 2026-05-15
- President and CEO · Common StockSold 8 257 @ $4,29$35K · 2026-05-15
- Corporate Secretary · Common StockOther 135 690 @ $4,23$574K · 2026-05-07
- Chief Operating Officer · Common StockOther 72 734 @ $4,18$304K · 2026-05-05
- Corporate Secretary · Common StockOther 76 147 @ $4,18$318K · 2026-05-05
- Chief People Officer · Common StockOther 56 778 @ $4,18$237K · 2026-05-05
- President and CEO · Common StockOther 335 922 @ $4,18$1,4M · 2026-05-05
- Chief Financial Officer · Common StockOther 92 652 @ $4,18$387K · 2026-05-05
Short positioning
16.7Mshares short+4.2% vs prior
10.9days to cover
59.2%short of daily vol
1.2Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AQST.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorCustomersPartners
Evidence & claims
From filings & derived data- Cash & equivalents (annual): USD 121.17MUnknown
- Shares outstanding (annual): 122.04MUnknown
- Cost of revenue (annual): USD 18.55MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -1Unknown
- EPS (basic) (annual): USD-PER-SHARES -1Unknown
- Long-term debt (annual): USD 45MUnknown
- Shareholders' equity (annual): USD -33.66MUnknown
- Current liabilities (annual): USD 47.61MUnknown
- Revenue (annual): USD 44.55MUnknown
- Total assets (annual): USD 160.43MUnknown
- Total liabilities (annual): USD 194.09MUnknown
- Pre-tax income (annual): USD -83.78MUnknown
- Operating cash flow (annual): USD -52.43MUnknown
- Current assets (annual): USD 149.27MUnknown
- Capex (annual): USD 562KUnknown
- Operating income (annual): USD -71.05MUnknown
- Net income (annual): USD -83.78MUnknown
- R&D expense (annual): USD 17.19MUnknown
- Shareholders' equity (annual): USD -60.16MUnknown
- Capex (annual): USD 159KUnknown
- Operating cash flow (annual): USD -35.76MUnknown
- Total liabilities (annual): USD 161.58MUnknown
- Shares outstanding (annual): 91.41MUnknown
- Cost of revenue (annual): USD 17.87MUnknown
Showing 24 of 33 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-16INSIDERBarber Daniel sold 20.4k sh — President and CEO ~$82k
2026-07-15INSIDERBarber Daniel sold 4.6k sh — President and CEO ~$19k
2026-06-23 00:00 UTCINSIDER11 insider transactions — 2026-06 · net sell $212k 7 derivative
2026-06-23 00:00 UTCINSIDER11 insider transactions — 2026-06 · net sell $212k 7 derivative
2026-06-23INSIDERKrop Julie sold 25.0k sh — Director ~$125k
2026-06-23INSIDERKrop Julie transacted 25.0k sh — Director ~$18k
2026-06-23INSIDERKrop Julie disposed of 25.0k sh Non-Qualified Stock Option (right to buy) — Director
2026-06-15INSIDERBarber Daniel sold 25.0k sh — President and CEO ~$104k
2026-06-10INSIDERJenkins Abigail L. disposed of 50.5k sh Non-Qualified Stock Option (right to buy) — Director
2026-06-10INSIDERCochran John acquired 50.5k sh Stock Option (Right to Purchase) — Director
2026-06-10INSIDERKrop Julie acquired 50.5k sh Stock Option (Right to Purchase) — Director
2026-06-10INSIDERMORRIS TIMOTHY E acquired 50.5k sh Stock Option (right to purchase) — Director
2026-06-10INSIDERTaglietti Marco acquired 50.5k sh Stock Option (Right to Purchase) — Director
2026-06-10INSIDERBROWN GREGORY B acquired 50.5k sh Stock Option (Right to Purchase) — Director
2026-06-08INSIDERKorczynski Sherry transacted 2.7k sh — Chief Commercial Officer
2026-05-18 00:00 UTCINSIDER10 insider transactions — 2026-05 · net sell $3.3M 1 derivative
2026-05-18 00:00 UTCINSIDER10 insider transactions — 2026-05 · net sell $3.3M 1 derivative
2026-05-18INSIDERZalewski Thomas A. transacted 100.0k sh — Chief Legal Officer
2026-05-18INSIDERZalewski Thomas A. acquired 75.0k sh Non-Qualified Stock Option (right to buy) — Chief Legal Officer
2026-05-15INSIDERCioffi Melina transacted 1.7k sh — SVP, Regulatory Affairs ~$7k
2026-05-15INSIDERBarber Daniel sold 8.3k sh — President and CEO ~$35k
2026-05-07INSIDERBRAENDER LORI J transacted 135.7k sh — Corporate Secretary ~$574k
2026-05-05INSIDERJung Cassie transacted 72.7k sh — Chief Operating Officer ~$304k
2026-05-05INSIDERBRAENDER LORI J transacted 76.1k sh — Corporate Secretary ~$318k
2026-05-05INSIDERBoyd Peter E. transacted 56.8k sh — Chief People Officer ~$237k
2026-05-05INSIDERBarber Daniel transacted 335.9k sh — President and CEO ~$1.40M
2026-05-05INSIDERTOTH A ERNEST JR transacted 92.7k sh — Chief Financial Officer ~$387k
Showing the 40 most recent of 42 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage